Dossier assessment
Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
First-line treatment of adult patients with primary advanced or recurrent mismatch repair proficient endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab in combination with olaparib
- Patients with newly diagnosed disease: hint of considerable added benefit
- Patients with recurrent disease: hint of lesser benefit
Project details
- Project no.
- A24-86
- Commission
- Commission awarded on 22.08.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-86_en
Connected Projects
-
Dossier assessment
Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Durvalumab (gastric or gastro-oesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed